2. Hosotani Y, Yasuda K, Nagai M, Yamanishi K, Kanazawa N, Gomi Fumi, Imai Y*. IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice. Allergol Int,72(2): 324-331,2023 //doi.org/10.1016/j.alit.2022.10.003 (* corresponding author)
3. Yamanaka K, Kono Y, Iida S, Nakanishi T, Nishimura M,Matsushima Y, Kondo M,Habe K, Imai Y*,The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis, Int. J. Mol. Sci.2023, 24(4), 3310; https://doi.org/10.3390/ijms24043310 (registering DOI) (* last author)
4. Miyamoto S, Imai Y*, Matsutani M, Nagai M, Yamanishi K, Kanazawa N, Nishiumi S, Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis, Disease Markers, vol. 2023, Article ID 9013756, 8 pages, 2023. https://doi.org/10.1155/2023/9013756 (* corresponding author)
5. Matsutani M, Imai Y*, Miyamoto S, Inoue Y, Natsuaki M and Kanazawa N (2024) Real-world efficacy of dupilumab re-administration after discontinuation in patients with atopic dermatitis. J Cutan Immunol Allergy 7:12480. doi: 10.3389/jcia.2024.12480 (* corresponding author)
6. Imai Y*. ILC2s in skin disorders, Allergol Int, 72(2),201-206,2023. https://doi.org/10.1016/j.alit.2023.01.002